  With the advent of deep generative models in computational chemistry, in
silico anticancer drug design has undergone an unprecedented transformation.
While state-of-the-art deep learning approaches have shown potential in
generating compounds with desired chemical properties, they disregard the
genetic profile and properties of the target disease. Here, we introduce the
first generative model capable of tailoring anticancer compounds for a specific
biomolecular profile. Using a RL framework, the transcriptomic profiles of
cancer cells are used as a context for the generation of candidate molecules.
Our molecule generator combines two separately pretrained variational
autoencoders (VAEs) - the first VAE encodes transcriptomic profiles into a
smooth, latent space which in turn is used to condition a second VAE to
generate novel molecular structures on the given transcriptomic profile. The
generative process is optimized through PaccMann, a previously developed drug
sensitivity prediction model to obtain effective anticancer compounds for the
given context (i.e., transcriptomic profile). We demonstrate how the molecule
generation can be biased towards compounds with high predicted inhibitory
effect against individual cell lines or specific cancer sites. We verify our
approach by investigating candidate drugs generated against specific cancer
types and find the highest structural similarity to existing compounds with
known efficacy against these cancer types. We envision our approach to
transform in silico anticancer drug design by leveraging the biomolecular
characteristics of the disease in order to increase success rates in lead
compound discovery.
